Featured Research

from universities, journals, and other organizations

Discovery Of A Molecule That Controls Bile Acids May Lead To New Cholesterol Drugs

Date:
June 1, 1999
Source:
University Of Texas Southwestern Medical Center
Summary:
The discovery that a nuclear receptor controls the production of bile acids and works within a pathway that speeds up destruction of cholesterol may lead to new cholesterol drugs, UT Southwestern researchers report.

DALLAS - May 21, 1999 - The discovery that a nuclear receptor controls the production of bile acids and works within a pathway that speeds up destruction of cholesterol may lead to new cholesterol drugs, UT Southwestern researchers reported in today's issue of Science.

Their finding -- that the receptor FXR (farnesoid orphan receptor) is integral to maintaining the balance of cholesterol and bile acids -- has important implications for developing drugs to control dietary cholesterol in humans, said corresponding author of the study Dr. David Mangelsdorf, associate professor of pharmacology and Howard Hughes Medical Institute (HHMI) investigator.

"Our finding that FXR functions as a bile-acid receptor suggests an expanded model for the regulation of cholesterol homeostasis by nuclear receptors," Mangelsdorf said. He and other researchers previously had shown that accumulation of dietary cholesterol in the liver triggers production of biochemicals called oxysterols. These substances activate liver orphan receptor (LXR) to speed up the breakdown of cholesterol for conversion to bile acids and steroid hormones.

"If we find an antagonist to FXR, then it might increase bile-acid production to control cholesterol," Mangelsdorf said. Both LXR and FXR are members of a family of protein molecules located in the nucleus of cells found in the liver, intestine, kidneys and adrenal glands. Their role in removing cholesterol from the body is important because it prevents arteriosclerosis, which leads to heart attacks.

This study showed that elevated bile acids regulated further production and transport through FXR. This leads Mangelsdorf to believe that FXR is one of the key regulators that controls repression and further synthesis in the liver and increases the production of other proteins that transport bile acids in the intestine.

"People can't live without bile acids as a way to rid the body of cholesterol, so our work characterizing these orphan receptors is becoming very significant in understanding cholesterol synthesis and metabolism," he said.

Orphan receptors are molecules believed to be the locks that control biochemical processes but whose function and ligand, or key, to activate the cellular changes, is unknown. FXR acts as the lock that binds with bile acids. When this happens, the receptor represses the gene to regulate the enzyme cholesterol 7 alpha-hydroxylase, which limits bile-acid synthesis. At the same time, it activates a gene that encodes I-BABP (intestinal bile-acid- binding protein). Mangelsdorf and his group of researchers believe that I-BABP transports the bile acid through the intestine wall.

Other UT Southwestern researchers involved in the study were Dr. Makoto "Mac" Makishima and Joyce Repa, HHMI associates. This was a collaborative effort with scientists from Tularik Inc. in San Francisco.

A grant from the Robert A. Welch Foundation funded the work.


Story Source:

The above story is based on materials provided by University Of Texas Southwestern Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

University Of Texas Southwestern Medical Center. "Discovery Of A Molecule That Controls Bile Acids May Lead To New Cholesterol Drugs." ScienceDaily. ScienceDaily, 1 June 1999. <www.sciencedaily.com/releases/1999/06/990601081146.htm>.
University Of Texas Southwestern Medical Center. (1999, June 1). Discovery Of A Molecule That Controls Bile Acids May Lead To New Cholesterol Drugs. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/1999/06/990601081146.htm
University Of Texas Southwestern Medical Center. "Discovery Of A Molecule That Controls Bile Acids May Lead To New Cholesterol Drugs." ScienceDaily. www.sciencedaily.com/releases/1999/06/990601081146.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins